百花医药
(600721)
| 流通市值：25.19亿 | | | 总市值：25.19亿 |
| 流通股本：3.84亿 | | | 总股本：3.84亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 290,630,947.61 | 196,304,097.42 | 90,876,390.38 | 369,277,391.9 |
| 营业收入 | 290,630,947.61 | 196,304,097.42 | 90,876,390.38 | 369,277,391.9 |
| 二、营业总成本 | 236,012,856.12 | 157,352,200.56 | 68,381,143.77 | 301,192,191.78 |
| 营业成本 | 155,589,054.18 | 102,564,923.99 | 43,388,729.57 | 188,193,449.02 |
| 税金及附加 | 3,721,878.72 | 2,606,022.39 | 1,204,203.13 | 5,247,684.19 |
| 销售费用 | 9,209,043.11 | 6,891,425.52 | 2,306,567.55 | 13,145,911.75 |
| 管理费用 | 46,193,235.34 | 31,980,216.22 | 15,804,970.01 | 63,602,116.61 |
| 研发费用 | 22,270,105.49 | 13,947,010.74 | 6,001,053.66 | 31,869,198.42 |
| 财务费用 | -970,460.72 | -637,398.3 | -324,380.15 | -866,168.21 |
| 其中:利息费用 | 0 | - | - | - |
| 其中:利息收入 | 1,042,753.09 | 692,465.37 | 361,031.44 | 1,021,476.03 |
| 加:公允价值变动收益 | - | - | - | 704,936 |
| 加:投资收益 | 2,560,123.26 | 1,744,495.09 | 254,724.16 | 1,249,827.77 |
| 资产处置收益 | 86,255.16 | 86,255.16 | 22,391.26 | 14,289.27 |
| 资产减值损失(新) | -26,424,038.92 | -12,991,463.31 | -89,833.55 | -49,331,386.72 |
| 信用减值损失(新) | -4,306,666.11 | -3,379,460.09 | -883,658.28 | -4,296,975.31 |
| 其他收益 | 608,191.12 | 465,992.08 | 181,874.59 | 1,530,052.52 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 27,141,956 | 24,877,715.79 | 21,980,744.79 | 17,955,943.65 |
| 加:营业外收入 | 113,097.83 | 98,579.81 | 98,579.81 | 124,803.95 |
| 减:营业外支出 | 202,501.4 | 177,265.78 | 59,602.69 | 1,599,205.52 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 27,052,552.43 | 24,799,029.82 | 22,019,721.91 | 16,481,542.08 |
| 减:所得税费用 | 3,099,308.23 | 2,138,044.2 | 1,356,262.89 | 3,509,204.13 |
| 六、净利润 | 23,953,244.2 | 22,660,985.62 | 20,663,459.02 | 12,972,337.95 |
| 持续经营净利润 | 23,953,244.2 | 22,660,985.62 | 20,663,459.02 | 12,972,337.95 |
| 归属于母公司股东的净利润 | 23,953,244.2 | 22,660,985.62 | 20,663,459.02 | 12,972,337.95 |
| (一)基本每股收益 | 0.06 | 0.06 | 0.05 | 0.03 |
| (二)稀释每股收益 | 0.06 | 0.06 | 0.05 | 0.03 |
| 八、其他综合收益 | - | - | - | -140,003.82 |
| 归属于母公司股东的其他综合收益 | - | - | - | -140,003.82 |
| 九、综合收益总额 | 23,953,244.2 | 22,660,985.62 | 20,663,459.02 | 12,832,334.13 |
| 归属于母公司股东的综合收益总额 | 23,953,244.2 | 22,660,985.62 | 20,663,459.02 | 12,832,334.13 |
| 公告日期 | 2024-10-25 | 2024-08-21 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |